GlassScriptPhysician profile
Melisa Ann Ardis
NPI 1619517620
$2,240.77
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $876 · 2022: $1,063 · 2023: $237 · 2024: $65.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.47 | 2021-2024 | |
| Lilly USA, LLC | $307.98 | 2021-2023 | Mounjaro, Jardiance |
| Amgen INC. | $157.58 | 2021-2023 | Evenity, Prolia |
| Novo Nordisk INC | $131.57 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.57 | 2021-2022 | |
| Amarin Pharma, INC. | $92.38 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $83.35 | 2021-2022 | |
| Pfizer INC. | $80.43 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.38 | 2021-2022 | |
| Dexcom, INC. | $69.16 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $64.48 | 2021-2023 | Verquvo, Belsomra, Januvia |
| Otsuka America Pharmaceutical, INC. | $62.41 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $60.34 | 2022-2023 | |
| Astellas Pharma US INC | $54.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.38 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.84 | 2021 | |
| Abbott Laboratories | $40.69 | 2022 | |
| Corium, LLC | $36.54 | 2022-2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.82 | 2022 | |
| Eisai INC. | $32.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $32.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.18 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.76 | 2022 | |
| Genentech USA, INC. | $23.57 | 2021 | |
| Daiichi Sankyo INC. | $18.48 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Ardis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.